Search clinical trials for: Afatinib (BIBW2992)

Total 235 results

Instituto Nacional de Cancerologia de Mexico

Completed

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | EGFR | HER-2

Mexico
Center Trials & Treatment Europe
Center Trials & Treatment

Active, not recruiting

Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma (DPTA)

Non Small Cell Lung Cancer

Georgia
Massachusetts General Hospital
Boehringer Ingelheim; University of Texas

Completed

Understanding Mechanisms of Acquired Resistance to BIBW2992

Non-small Cell Lung Cancer | EGFR Mutations

United States
Instituto Nacional de Cancerologia de Mexico

Completed

Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)

Lung Cancer | Skin Rash

Mexico
Boehringer Ingelheim

Completed

Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

Carcinoma, Non-Small-Cell Lung

Belgium, Spain
UNICANCER

Completed

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients (PREDICTOR)

Carcinoma, Squamous Cell of Head and Neck

France
Yonsei University

Unknown

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Squamous Cell Carcinoma of Esophagus

Korea, Republic of
Boehringer Ingelheim

Completed

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Breast Neoplasms

United States, Australia, Hong Kong, Korea, Republic of, Thailand, Tunisia, United Kingdom
Boehringer Ingelheim

Completed

BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

Carcinoma, Non-Small-Cell Lung

Italy
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Completed

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer | Squamous Cell Cancer

United States
Boehringer Ingelheim

Completed

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

Glioblastoma

United Kingdom
University College, London
Boehringer Ingelheim

Completed

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Centre Leon Berard
Boehringer Ingelheim

Completed

Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck (BIBW2992ORL)

Head and Neck Squamous Cell Carcinoma

France
University of California, Davis
National Cancer Institute (NCI)

Completed

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
The Netherlands Cancer Institute
AstraZeneca; Boehringer Ingelheim

Unknown

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer (M14AFS)

Gastrointestinal Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms

Netherlands
Boehringer Ingelheim

Active, not recruiting

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Head and Neck Neoplasms

Korea, Republic of, China, Taiwan, Thailand, Philippines, India, Egypt, Hong Kong
Boehringer Ingelheim

Completed

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Lung Neoplasms

Hong Kong, Korea, Republic of, Spain, Singapore, China, United Kingdom, Taiwan, Canada, Australia, Germany, Ireland, Sweden, France, Norway
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Boehringer Ingelheim

Completed

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Russian Federation, South Africa, Spain, Sweden, Switzerland
Boehringer Ingelheim

Completed

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Neoplasms

United Kingdom
University of Washington

Completed

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Advanced Malignant Solid Neoplasm | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Recurrent Malignant Solid Neoplasm | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Bile Duct Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Aalborg University

Not yet recruiting

Investigation of Corticospinal Excitability Aspects of Itch and Pain

Pain | Itch
Aalborg University

Recruiting

Investigate the Relationship Between Catastrophizing and the Perception of Itch Intensity in Healthy Individuals

Histamine | Cowhage

Denmark
Institute for Clinical and Experimental Medicine

Not yet recruiting

Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure (LUNG-HF)

Heart Failure | Pulmonary Hypertension | Pulmonary Vascular Resistance Abnormality

Czechia
Massachusetts General Hospital
Boehringer Ingelheim; Incyte Corporation

Recruiting

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor | Unresectable Solid Tumor

United States
Central Adelaide Local Health Network Incorporated
University of Adelaide

Recruiting

Effect of Chitodex Gel in Tympanoplasty Surgery

Surgery | Otitis Media | Tympanic Membrane Perforation | Tympanic Membrane Inflammation

Australia
Jeeyun Lee

Not yet recruiting

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Stomach Neoplasm
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
National University Hospital, Singapore

Recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-small Cell Lung Cancer

United States
Fujian Cancer Hospital

Not yet recruiting

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
AIPING ZHOU

Recruiting

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Esophagus Squamous Cell Carcinoma

China
Pfizer

Recruiting

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Non-Small Cell Lung Cancer

Norway
Peking University

Recruiting

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

Advanced Esophageal Squamous Cell Carcinoma

China
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Huashan Hospital
Boehringer Ingelheim

Not yet recruiting

Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Chordoma of Clivus

China
West China Hospital

Recruiting

Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma (neoCHANCE-1)

Head and Neck Cancer

China
West China Hospital

Recruiting

Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC (neoCHANCE-2)

Head and Neck Squamous Cell Carcinoma

China
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

Pilot Trial for Treatment of Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | Recurrent Disease

Canada
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands, Italy
Amsterdam UMC, location VUmc

Recruiting

Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION)

Non-Small Cell Lung Cancer

Netherlands
Qingdao Central Hospital

Recruiting

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

PFS

China
National Taiwan University Hospital

Recruiting

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

NSCLC Stage IV

Taiwan
Peking University

Recruiting

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Esophageal Squamous Carcinoma

China

Search clinical trials for: Afatinib (BIBW2992)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations